Evidence map›Paper›PMID 22517363›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2012

ICAM-1 and nanomedicine: nature's doorway to the extravascular tissue realm.

Gregory M Lanza

Abstract readEditorialComment
PubMed Publisher
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Gregory M Lanza

Funding

Task Specific Project 3: Diffuse Optical TomographyU54CA136398 · NCI · WASHINGTON UNIVERSITY · PI WANG, LIHONG · 2008 to 2012
$6.0M
Theranostic Approach to Asthma Using Anti-Angiogenic NanomedicineR01HL113392 · NHLBI · WASHINGTON UNIVERSITY · PI LANZA, GREGORY M, WAGNER, ELIZABETH · 2012 to 2016
$3.3M
Characterization/bioinformatics-modeling of nanoparticle:complement interactionsU01NS073457 · NINDS · WASHINGTON UNIVERSITY · PI HOURCADE, DENNIS EMIL · 2010 to 2012
$3.0M
NEXT GENERATION APPROACHES TO BREAST CANCER USING IMAGE GUIDED DRUG DELIVERYR01CA154737 · NCI · WASHINGTON UNIVERSITY · PI LANZA, GREGORY M, PAN, DIPANJAN · 2011 to 2015
$2.4M
Fibrin-Specific Thrombolytic Nanoparticles for Acute StrokeR01NS059302 · NINDS · WASHINGTON UNIVERSITY · PI LANZA, GREGORY M · 2007 to 2011
$1.7M
TARGETED NANOTHERAPY IN THE TREATMENT OF INFLAMMATORY ARTHRITISR01AR056468 · NIAMS · WASHINGTON UNIVERSITY · PI PHAM, CHRISTINE T. · 2008 to 2012
$1.6M
Prevention of Bladder Cancer with Broccoli SproutsR21CA100623 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI ZHANG, YUESHENG · 2004 to 2005
$466k
NCI NIH HHS CA100623NCI NIH HHS CA136398NCI NIH HHS CA154737NHLBI NIH HHS HL113392NIAMS NIH HHS AR056468NINDS NIH HHS NS059302NINDS NIH HHS NS073457
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsCeramidesDrug CarriersEndocytosisEndothelium, VascularHumansIntercellular Adhesion Molecule-1Sphingomyelin PhosphodiesteraseCeramidesDrug CarriersIntercellular Adhesion Molecule-1Sphingomyelin Phosphodiesterase

Identifiers

PMID22517363

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.